DEF: Telomir Pharmaceuticals Sets Annual Meeting Date

Telomir Pharmaceuticals, Inc. has issued a proxy statement detailing its upcoming Annual Meeting of Shareholders, scheduled for September 11, 2026, to elect directors, ratify auditor appointment, and address other business.

Summary

• Telomir Pharmaceuticals, Inc. is holding its Annual Meeting of Shareholders virtually on September 11, 2026, at 11:00 a.m. Eastern Time.
• Shareholders will vote on electing four directors, ratifying the appointment of Salberg & Company, P.A. as the independent auditor for fiscal year 2026, and approving the adjournment of the meeting if necessary.
• The record date for determining shareholders entitled to vote is July 21, 2026, with 68,774,954 shares of Common Stock outstanding.
• The Board of Directors recommends voting FOR all proposals.
• The meeting will be conducted exclusively online via live audio-only webcast.
• Shareholders can vote by internet, mail, or virtually during the meeting.
• The filing also details executive compensation, security ownership, and related party transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily concerns procedural matters for an annual shareholder meeting and does not contain significant new financial performance data or strategic announcements.

Positives

• The company is holding its annual shareholder meeting, indicating ongoing corporate operations and governance.
• The virtual format aims to provide greater access for shareholders.
• The Board of Directors is recommending favorable votes for director elections and auditor ratification.
• Independent directors have been identified, meeting Nasdaq listing rules.
• The company has adopted a code of business conduct and ethics and an insider trading policy.

Negatives

• The company has experienced significant turnover in its Chief Financial Officer position, with three individuals holding the role between June 2024 and June 2026.
• The company's insider trading policy prohibits hedging, which could limit shareholder flexibility.
• The company has not maintained any retirement plans for its employees.
• The company's stock options were repriced in May 2026, reducing the exercise price for some options, which could indicate prior underperformance or a strategy to retain talent.

Risks

• If a quorum is not present or sufficient votes are not received, the meeting may be adjourned, delaying key decisions.
• The Director Election Proposal is a non-routine matter, meaning broker discretionary voting is not allowed, and a lack of shareholder instructions could lead to broker non-votes impacting the outcome.
• The company's insider trading policy prohibits hedging, which could limit shareholder flexibility in managing their investment risk.
• The company has not disclosed specific financial performance metrics or future guidance in this proxy statement, making it difficult to assess its current financial health or future prospects.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines proposals for the annual meeting, including director elections and auditor ratification, and details executive compensation and corporate governance matters.

Management Comments

• The Board recommends that shareholders vote FOR each of the Proposals.
• The company is making proxy materials available electronically via the Internet to save expenses and extra work.
• The Board has adopted a code of business conduct and ethics, an insider trading policy, and corporate governance guidelines.
• The company believes that its officers, directors, and greater than 10% owners timely filed all Section 16(a) reports during fiscal year 2025.

Industry Context

StockSavvy.ai notes that Telomir Pharmaceuticals is holding its annual shareholder meeting, a standard corporate governance event. The focus on director elections, auditor ratification, and virtual meeting format is typical for publicly traded companies. The details on executive compensation and related party transactions are crucial for understanding internal financial dealings and management incentives within the pharmaceutical sector.

Comparison to Industry Standards

• The virtual meeting format is becoming increasingly common across industries, including pharmaceuticals, to enhance shareholder accessibility and reduce logistical costs.
• The appointment of Salberg & Company, P.A. as auditor is a standard procedure, with audit fees of $87,000 for 2025 and audit-related fees of $18,000, which appear within a reasonable range for a company of its size, though direct comparison is difficult without more financial data.
• The compensation structure for CEO Erez Aminov, including a base salary of $500,000 effective January 1, 2026, and significant stock and option awards, aligns with compensation trends for CEOs in early-stage or clinical-stage pharmaceutical companies, though the total compensation can be highly variable based on equity grants.
• The company's related party transactions, particularly the equity financing from The Bayshore Trust and advances from MIRALOGX and The Starwood Trust, are common in early-stage companies seeking capital from significant stakeholders.

Management Changes

Corporate Governance

Related Party Transactions

• MIRALOGX shipped pharmaceutical chemicals to Telomir's service provider for research at a cost of approximately $224,800 during the year ended December 31, 2025.
• The Company received working capital advances from MIRALOGX and The Starwood Trust, which are due on demand and non-interest bearing.
• The Company entered into an unsecured Promissory Note and Loan Agreement with the Starwood Trust for up to $5 million, bearing 7% simple interest, with no amounts borrowed as of December 31, 2025.
• Starwood Trust purchased $1.0 million of unregistered common stock from the Company.
• The Company issued restricted common stock to The Bayshore Trust for $3 million in equity financing.
• 400,000 fully vested common shares were granted to Chairman and CEO Erez Aminov on May 27, 2025, valued at $840,000.
• Mr. Aminov transferred $155,518 to the Company for payroll withholding taxes related to his RSU grant, which was later returned to him in January 2026.

Stakeholder Impact

• Shareholders will have the opportunity to vote on director elections and auditor ratification, influencing the company's leadership and financial oversight.
• The virtual meeting format may increase shareholder participation.
• Executive compensation details, including salary increases and equity awards, may impact employee morale and shareholder perception of management alignment.
• Related party transactions, particularly capital raises from affiliated entities, could be viewed positively for securing funding but may raise concerns about potential conflicts of interest for some shareholders.

Next Steps

• Shareholders are encouraged to vote their shares by internet or mail prior to the meeting.
• The company will hold its Annual Meeting of Shareholders on September 11, 2026.
• Final voting results will be published in a Form 8-K within four business days after the meeting.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting and does not contain new financial performance data, strategic updates, or significant risk disclosures that would warrant a buy or sell recommendation. The focus is on governance and procedural matters.

Keywords

Annual Meeting, Proxy Statement, Director Election, Auditor Ratification, Shareholder Vote, Virtual Meeting, Corporate Governance, Executive Compensation